EPIRUS Biopharmaceuticals, Inc. (EPRSQ) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
EPRSQ representa a EPIRUS Biopharmaceuticals, Inc., una empresa del sector Healthcare con un precio de $0.00 (capitalización de mercado 2K). Calificado con 46/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 3 mar 2026EPIRUS Biopharmaceuticals, Inc. (EPRSQ) Resumen de Asistencia Médica y Tuberías
EPIRUS Biopharmaceuticals aimed to revolutionize treatment for inflammatory diseases and ultra-rare blood disorders through biosimilar development, offering potential cost-effective alternatives, before filing for Chapter 7 liquidation in 2016, ceasing operations and development.
Tesis de Inversión
Investing in EPRSQ is not advisable due to the company's Chapter 7 liquidation filing in 2016. The company's assets are being liquidated, and there is no ongoing business operation. The potential for return on investment is extremely low. The company's pipeline of biosimilar product candidates, including BOW015, BOW050, BOW070, BOW080, and BOW100, are no longer under development. The company's market capitalization is effectively zero, reflecting its defunct status. Investors should be aware of the high risk associated with investing in companies undergoing liquidation.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Lead product candidate BOW015 was a biosimilar version of Remicade (infliximab) targeting inflammatory diseases.
- Pipeline included biosimilars for Humira (adalimumab), Actemra (tocilizumab), Soliris, and SIMPONI.
- Collaborations with Sun Pharmaceutical Industries Ltd., Livzon Mabpharm Inc., and Polpharma S.A.
- Filed for Chapter 7 liquidation on July 25, 2016.
- Market capitalization is $0.00B, reflecting its defunct status.
Competidores y Pares
Fortalezas
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.
Debilidades
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.
Catalizadores
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.
Riesgos
- Ongoing: Liquidation risk due to Chapter 7 bankruptcy filing.
- Ongoing: No ongoing business operations.
- Ongoing: No potential for future revenue generation.
Oportunidades de crecimiento
- Growth opportunity 1: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
- Growth opportunity 2: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
- Growth opportunity 3: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
- Growth opportunity 4: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
- Growth opportunity 5: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
Oportunidades
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.
Amenazas
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.
Ventajas competitivas
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no competitive advantages associated with the company.
Acerca de EPRSQ
Founded in 2011 and headquartered in Boston, Massachusetts, EPIRUS Biopharmaceuticals, Inc. was a biopharmaceutical company dedicated to developing, manufacturing, and commercializing biosimilar therapeutics on a global scale. The company's core strategy revolved around creating biosimilar versions of established biologic drugs, offering potentially more affordable treatment options for a range of diseases. Their lead product candidate was BOW015, a biosimilar version of Remicade (infliximab), targeting inflammatory diseases. The pipeline also included BOW050, a biosimilar of Humira (adalimumab); BOW070, a biosimilar of Actemra (tocilizumab); BOW080, a biosimilar of Soliris; and BOW100, a biosimilar of SIMPONI. These biosimilars were intended to treat a variety of conditions, including rheumatoid arthritis, inflammatory bowel disease, and ultra-rare blood disorders. EPIRUS established strategic collaborations and licensing agreements with companies like Sun Pharmaceutical Industries Ltd., Livzon Mabpharm Inc., and Polpharma S.A. to support its development and commercialization efforts. However, on July 25, 2016, EPIRUS Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court, effectively halting its operations and development programs.
Qué hacen
- Developed biosimilar therapeutics.
- Aimed to manufacture biosimilar versions of existing biologic drugs.
- Focused on treatments for inflammatory diseases and ultra-rare blood disorders.
- Sought to commercialize biosimilars globally.
- Partnered with other pharmaceutical companies for development and distribution.
- Filed for Chapter 7 liquidation in 2016.
Modelo de Negocio
- Develop biosimilar versions of branded biologic drugs.
- Out-license or co-develop biosimilars with partners.
- Commercialize biosimilars directly or through partners.
- Generate revenue through product sales and licensing fees.
Contexto de la Industria
The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Companies like ALNAQ, ARTH, GNRS, GWHP, and INTP operate in this space. The biosimilar market offers opportunities for companies to develop and commercialize cost-effective alternatives to existing biologic drugs. However, the industry also faces challenges such as patent disputes, regulatory hurdles, and pricing pressures. EPIRUS Biopharmaceuticals aimed to capitalize on the biosimilar market but ultimately failed due to financial constraints, leading to its liquidation.
Clientes Clave
- Patients suffering from inflammatory diseases.
- Healthcare providers prescribing biologic drugs.
- Hospitals and clinics using biologic treatments.
- Pharmaceutical companies partnering for distribution.
Finanzas
Gráfico e información
Precio de la acción de EPIRUS Biopharmaceuticals, Inc. (EPRSQ): $0.00 (-0.00, -99.00%)
Últimas noticias
No hay noticias recientes disponibles para EPRSQ.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para EPRSQ.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para EPRSQ.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de EPRSQ en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Información del mercado OTC de EPRSQ
EPRSQ cotiza en el nivel de mercado OTC Other de OTC Markets.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
Lo Que los Inversores Preguntan Sobre EPIRUS Biopharmaceuticals, Inc. (EPRSQ)
¿Cuáles son los factores clave para evaluar EPRSQ?
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) actualmente tiene una puntuación IA de 46/100, indicando puntuación baja. Fortaleza clave: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.. Riesgo principal a monitorear: Ongoing: Liquidation risk due to Chapter 7 bankruptcy filing.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de EPRSQ?
EPRSQ actualmente puntúa 46/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de EPRSQ?
Los precios de EPRSQ se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre EPRSQ?
La cobertura de analistas para EPRSQ incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en EPRSQ?
Las categorías de riesgo para EPRSQ incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Liquidation risk due to Chapter 7 bankruptcy filing.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de EPRSQ?
La relación P/E para EPRSQ compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está EPRSQ sobrevalorada o infravalorada?
Determinar si EPIRUS Biopharmaceuticals, Inc. (EPRSQ) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de EPRSQ?
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Company filed for Chapter 7 liquidation in 2016. Information is based on historical data prior to liquidation.